ABHH holds the biggest event on Lymphoma and CLL of Latin Americal Register and attend!
Carlos Sérgio Chiattone - FCM of Santa Casa de São Paulo and Hospital Samaritano - SP
Jorge Vaz Pinto Neto - Cettro (Centro de Câncer de Brasília)
Natalia Zing - BP A Beneficência Portuguesa de São Paulo
Talita Silveira - AC Camargo Cancer Center
Thais Fisher - AC Camargo Cancer Center
Oslo University Hospital
Novant Health Cancer Institute
IRCCS San Raffaele Scientific Institute
Southampton NCRI/CR UK Experimental Cancer Medicines Centre
Rutgers Cancer Institute of New Jersey
The University of Melbourne
Nottingham University Hospitals NHS Trust
University of Miami Health System
IOSI/ Oncology Institute of Southern Switzerland
Institut Català d'Oncologia
Johannes Gutenberg University
Zucker School of Medicine at Hofstra/Northwell
MD Anderson Cancer Center
Weill Cornell Medicine
University of Rochester Medical Center
University College London Hispitals - UCLH
University of British Columbia
National Cancer Institute, National Institutes of Health
The Finsen Centre, National Hospital
University of Modena and Reggio Emilia
MD Anderson Cancer Center
University of Virginia Cancer Center
Università Vita-Salute San Raffaele
St James's University Hospital
Faculdade de Medicina de Botucatu – UNESP
Faculdade de Medicina de Ribeirão Preto – USP
Mayo Clinic, Rochester
University of Modena and Reggio Emilia (Italy)
Faculdade de Medicina da Universidade de São Paulo - USP e Fundação Pró-Sangue Hemocentro de São Paulo.
International speakers’ lectures will be subtitled.
The Live sessions of Questions and Answers will rely on simultaneous translation (English/Portuguese).
Please select the language-corresponding flag on the upper corner of the screen.
Title | Speaker | ||
---|---|---|---|
13:30 | 13:45 | Opening | President ABHH: Dante Langhi Jr. (São Paulo, SP) President BLC: Carlos Sérgio Chiattone (São Paulo, SP) |
13:45 | 14:30 | Session 1: Diffuse Large B-cell Lymphoma | |
13:45 | 13:50 | Introduction | Moderator: Daniel Tabak (Rio de Janeiro, RJ) |
13:50 | 14:10 | High-risk Diffuse Large B-cell Lymphoma: Is there anything definitively better than R-CHOP? | Speaker: Christopher Fox (Nottingham, UK) |
14:10 | 14:30 | Which is the best second-line option for patients NOT eligible for transplant? | Speaker: Andrew Davies (Southampton, UK) |
14:30 | 15:15 | Session 2: High-Grade Lymphomas | |
14:30 | 14:35 | Introduction | Moderator: Nelson Spector (Rio de Janeiro, RJ) |
14:35 | 14:55 | Is DA-EPOCH-R the best option for Primary Mediastinal Lymphoma? Do we still need radiotherapy for consolidation? | Speaker: Kerry Savage (Vancouver, CA) |
14:55 | 15:15 | Burkitt Lymphoma in adults: “Is there a standard treatment?” | Speaker: Mark Roschewski (Bethesda, USA) |
15:15 | 16:00 | Session 3: Lymphomas & CNS | |
15:15 | 15:20 | Introduction | Moderator: Talita Silveira (São Paulo, SP) |
15:20 | 15:40 | Primary CNS Lymphoma: What is new for 2021? | Speaker: Andrés Ferreri (Milão, IT) |
15:40 | 16:00 | How to define risk and how to perform prophylaxis for secondary CNS infiltration? | Speaker: Kate Cwynarski (Londres, UK) |
16:00 | 16:15 | Break | |
16:15 | 17:05 | Questions & Answers Live | Participants: Speakers and Moderators of the Sessions 1, 2 and 3 |
17:05 | 17:15 | Break | |
17:15 | 18:00 | Corporate Symposium Roche * - The future of 1L DLBCL treatment: a chat with experts | Experts: Andrew Davies (Southampton, UK) Samir Kanaan Nabhan (Curitiba, PR) |
18:00 | 18:15 | Break | |
18:15 | 19:00 | Corporate Symposium Zodiac * - The role of the BTKi in RR setting of Mantle Cell Lymphoma treatment | Chairman: Celso Arrais (São Paulo, SP) Speaker: Tam Constantine (Melbourne, AUS) |
Title | Speaker | ||
---|---|---|---|
13:30 | 14:15 | Corporate Symposium * – Janssen Current and future approaches for R/R MCL treatment |
Speaker: Georg Hess (Mainz, Alemanha) |
14:15 | 14:30 | Break | |
14:30 | 15:15 | Corporate Symposium * – Astrazeneca Unraveling the Treatment of Mantle Cell Lymphoma |
Moderator: Carlos Sérgio Chiattone (São Paulo, SP) Speakers: Celso Arrais (São Paulo, SP) Alan Skarbnik (Charlotte, EUA) |
15:15 | 15:30 | Break | |
15:30 | 16:15 | Session 4: Marginal Zone Lymphoma and Mantle Cell Lymphoma | |
15:30 | 15:35 | Introduction | Moderator: Rony Schaffel (Rio de Janeiro, RJ) |
15:35 | 15:55 | MALT Lymphoma: lessons learned from the "International Extranodal Lymphoma Study Group” | Speaker: Emanuele Zucca (Bellinzona, CH) |
15:55 | 16:15 | Novel Therapies for Mantle Cell Lymphoma Post 2020 | Speaker: Michael Wang (Houston, USA) |
16:15 | 17:00 | Session 5: Follicular Lymphoma | |
16:15 | 16:20 | Introduction | Moderator: Adriana Scheliga (Rio de Janeiro, RJ) |
16:20 | 16:40 | Deciding on Rituximab versus Obinutuzumab for Follicular Lymphoma | Speaker: Jonathan Friedberg (Rochester, USA) |
16:40 | 17:00 | Which is the best approach in R/R Follicular Lymphoma? | Speaker: John P. Leonard (New York, USA) |
17:00 | 17:30 | Corporate Symposium - Bristol* What do I need to know to manage lenalidomide in indolent Lymphomas? |
Speaker: John P. Leonard (New York, USA) |
17:30 | 17:40 | Break | |
17:40 | 18:00 | Questions & Answers Live | Participants: Speakers and Moderators of the Sessions 4 and 5 |
18:00 | 18:15 | Break | |
18:15 | 19:15 | Corporate Symposium – Takeda* 5-year follow-up: Echelon-1 & Echelon-2 |
Moderator: Carlos Sérgio Chiattone (São Paulo, SP) |
18:15 | 18:35 | ECHELON-1 5y follow-up | Speaker: Martin Hutchings (Copenhagen, DK) |
18:35 | 18:55 | ECHELON-2 5y follow-up | Speaker: Eva Domingo (Barcelona, ES) |
18:55 | 19:15 | Questions & Answers | |
19:15 | 19:30 | Break | |
19:30 | 20:45 | Launch Symposium MSD * - The first Anti-PD1 approved in Brazil for Refractory or Relapsed CHL after the first line treatment. | Speakers: Otavio Baiocchi (São Paulo, SP) Guilherme Perini (São Paulo – SP) Adriana Scheliga (Rio de Janeiro, RJ) |
19:30 | 19:40 | Opening/ Immunotherapy: New treatment paradigm | Speaker: Otávio Baiocchi (São Paulo, SP) |
19:40 | 19:55 | Keytruda: New treatment standard for Relapsed or Refractory CHL (Clinical Case KN204) | Speaker: Guilherme Perini (São Paulo, SP) |
19:55 | 20:10 | Quality of life, safety profile, and treatment management with Immunotherapy in the clinical practice | Speaker: Adriana Scheliga (Rio de Janeiro, RJ) |
20:10 | 20:30 | From specialist to specialist – Hot Topics of immunotherapy | Speaker:All |
20:30 | 20:35 | Final Remarks |
Title | Speaker | ||
---|---|---|---|
13:30 | 14:15 | Corporate Symposium – Libbs* Perspective on DLBCL and FL treatment: What is the future of rituximab in R/R disease? | Speaker: Guilherme Perini (São Paulo, SP) |
14:15 | 14:25 | Break | |
14:25 | 15:05 | Session 6: CAR T-cell Therapy for Lymphomas | |
14:25 | 14:30 | Introduction | Moderator: Samir Kannan Nabhan (Curitiba,PR) |
14:30 | 14:50 | CAR T-cell Therapy: The current scenario in Brazil | Speaker: Renato Cunha (Ribeirão Preto, SP) |
14:50 | 15:10 | CAR T-cell Therapy versus ASCT for R/R B-cell NHL | Palestrante: Vanderson Rocha (São Paulo, SP) |
15:10 | 15:55 | Session 7: Peripheral T-Cell Lymphoma | |
15:10 | 15:15 | Introduction | Moderator: Carlos Sérgio Chiattone (São Paulo, SP) |
15:15 | 15:35 | PTCL Relapsed/Refractory: are we improving? | Speaker: Owen O’Connor (Charlottesville, USA) |
15:35 | 15:55 | Lessons from the International T-cell Project 2.0 | Speaker: Massimo Federico (Modena, IT) |
15:55 | 16:10 | Break | |
16:10 | 16:35 | Questions & Answers Live | Participants: Speakers and Moderators of the Sessions 6 and 7 |
16:35 | 17:20 | Session 8: Hodgkin Lymphoma | |
16:35 | 16:40 | Introduction | Moderador: Otavio Baiocchi (São Paulo, SP) |
16:40 | 17:00 | Hodgkin Lymphoma Treatment: when is less good enough? | Speaker: Martin Hutchings (Copenhagen, DK) |
17:00 | 17:20 | New Strategies to optimize the Outcomes in R/R Hodgkin Lymphomas | Speaker: Craig Moskowitz (Miami, USA) |
17:20 | 18:05 | Session 9: Chronic Lymphocytic Leukemia (1 st part) | |
17:20 | 17:25 | Introduction | Moderator: Guilherme Perini (São Paulo, SP) |
17:25 | 17:45 | Options for a High-Risk patient requiring first-line therapy | Speaker: Jan Burger (Houston, USA) |
17:45 | 18:05 | How should we sequence and combine novel therapies in CLL? | Speaker: Jacqueline Barrientos (Nova York, USA) |
18:05 | 18:15 | Break | |
18:15 | 18:45 | Questions & Answers Live | Participants: Speakers and Moderators of the Sessions 8 and 9 |
18:50 | 19:00 | Break | |
19:00 | 19:45 | Corporate Symposium - Janssen * Biological insights in high risk CLL |
Speaker: Jan Burger (Houston, US) |
Title | Speaker | ||
---|---|---|---|
09:00 | 09:45 | Corporate Symposium - Abbvie * | |
09:00 | 09:05 | Welcome | Moderator: Carlos Sérgio Chiattone (São Paulo -SP) |
09:05 | 09:35 | CLL R/R updates | Speaker: Peter Hillmen (Leeds, UK) |
09:35 | 09:45 | Questions & Answers | |
09:45 | 10:00 | Break | |
10:00 | 10:45 | Session 10: Chronic Lymphocytic Leukemia (2 nd part) | |
10:00 | 10:05 | Introduction | Moderator: Celso Arrais (São Paulo, SP) |
10:05 | 10:25 | Fixed Duration Therapy (MRD-based) versus continuous therapy for CLL: how to choose | Speaker: Peter Hillmen (Leeds, UK) |
10:25 | 10:45 | Targeted therapies in CLL: mechanisms of resistance and strategies for management | Speaker: Paolo Ghia (Milão, IT) |
10:45 | 11:30 | Session 11: Lymphoproliferative Disorders: Challenges in elderly patients | |
10:45 | 10:50 | Introduction | Moderator: Jorge Vaz Pinto Neto (Brasília, DF) |
10:50 | 11:10 | How to manage DLBCL in elderly patients? | Speaker: Stefano Luminari (Modena, IT) |
11:10 | 11:30 | What should we know about managing older patients with Hodgkin Lymphoma? | Speaker: Andrew Evens (Nova Jersey, USA) |
11:30 | 12:15 | Session 12: Emerging situations that accompany Lymphomas | |
11:30 | 11:35 | Introduction | Moderator: Jayr Schmidt Filho (São Paulo, SP) |
11:35 | 11:55 | Castleman Disease | Speaker: Alexander Fossa (Oslo, NO) |
11:55 | 12:15 | Hematophagocytic Lymphohistiocytosis (Hematophagocytic Syndrome) | Speaker: Rafael Gaiolla (Botucatu, SP) |
12:15 | 12:30 | Break | |
12:30 | 13:20 | Questions & Answers Live | Participants: Speakers and Moderators of the Sessions 10, 11 and 12 |
13:20 | 13:30 | Break | |
13:30 | 14:25 | Magna Conference | |
13:30 | 13:35 | Introduction | Moderator: Carmino Antonio de Souza (SP) |
13:35 | 14:15 | The high cost of drugs: Causes and solutions | Speaker: Vincent Rajkumar (Rochester, USA) |
14:15 | 14:25 | Questions & Answers Live | Participants: Carmino Antonio de Souza (Campinas, SP) Vincent Rajkumar (Rochester, US) Carlos Chiattone (São Paulo, SP) |
14:25 | 14:30 | Closing Remarks | President BLC: Carlos Sérgio Chiattone (São Paulo, SP) |
* The content of the Corporate Symposia is for prescribers only, following ANVISA Resolution RDC96 / 2008.